Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SURMODICS INC Earnings Release 2018

Nov 9, 2018

32845_rns_2018-11-09_5d0b59c5-eaf9-41ac-a6b4-536614487542.zip

Earnings Release

Open in viewer

Opens in your device viewer

8-K 1 a51897005.htm SURMODICS, INC. 8-K Copyright 2018 Business Wire, a Berkshire Hathaway company. All rights reserved www.businesswire.com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

| November
9, 2018 |
| --- |
| Date of report (Date of earliest event reported) |

Surmodics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Minnesota 0-23837 41-1356149
(State of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
9924 West 74 th Street Eden Prairie, Minnesota 55344
(Address
of Principal Executive Offices) (Zip
Code)
(952) 500-7000
(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On November 9, 2018, Surmodics, Inc. (the “ Company ”) issued a press release (the “ Press Release ”) announcing the results for the quarter ended September 30, 2018. A copy of the full text of the Press Release is furnished as Exhibit 99.1 to this report.

The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)
Exhibit Number Description
99.1 Press Release dated November 9, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Timothy J. Arens
Timothy J. Arens
Vice President of Corporate Development and Strategy, Interim Vice President of Finance and Chief Financial Officer

EXHIBIT INDEX

Exhibit
Number Description
99.1 Press Release dated November 9, 2018.